Glaukos Corporation (GKOS) Misses Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Britain will not join Canada-led defence bank initiativeĀ
- CAE agrees to sell Flightscape unit to SITA for $500 million
Glaukos Corporation Announces Second Quarter 2017 Financial Results
August 2, 2017 4:10 PM EDTSAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced financial results for the second quarter ended June 30, 2017. Key highlights include:
Achieved 45% net sales growth to $41.3 million in the second quarter of 2017, compared to $28.6 million in the second quarter of 2016. Increased gross margin to 87% in the second quarter of 2017, compared to 85% in the second quarter of 2016.... More


